Anti–LAG-3/Anti–PD-1 Combo Demonstrates Sustained Efficacy in Melanoma
Source: Targeted Oncology, April 2025
Meredith McKean, MD, MPH, director of melanoma and skin cancer research at Sarah Cannon Research Institute, discusses the background and goals from the recent long-term follow-up of a phase 1 study (NCT03005782) evaluating the combination of fianlimab, an anti–LAG-3 agent, and cemiplimab (Libtayo), an anti–PD-1 agent, in patients with advanced melanoma.
The first-in-human, phase 1, open-label, dose-escalation and cohort expansion trial sought to evaluate the safety and pharmacokinetics to determine the selected dose level(s) for expansion of fianlimab as monotherapy and in combination with cemiplimab in patients with advanced malignancies.
“The goals of this additional follow-up were to be able to have additional follow-up on the primary end point of objective response rates and then be able to look at some of the additional secondary end points of progression-free survival and duration of response. We were trying to build on some of that initial data, looking for the durability of those initial responses for patients,” explains McKean.